Seegene, Inc.
Financials
Valuation Metrics
Seegene, Inc.'s Market Cap is ₩1.8T. At end of 2025 it was ₩1.1T. Ranked #233 of 2,419 in KR market (top 10%), #54 of 1,638 on KOSDAQ (top 3%), #22 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 10%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.81T KRW | KR#233/2,419 Sec#22/231 |
| Revenue | 509.27B KRW | KR#615/2,419 Sec#32/231 |
| Net Income | 80.29B KRW | KR#294/2,419 Sec#20/231 |
| Total Assets | 1.27T KRW | KR#418/2,419 Sec#21/231 |
| Net Assets | 1.04T KRW | KR#287/2,419 Sec#16/231 |
| Employees | 862 | KR#293/2,419 Sec#23/231 |
| Value | ||
| P/E | 22.56x | KR#1,207/2,419 Sec#70/231 |
| P/B | 1.74x | KR#1,828/2,419 Sec#128/231 |
| P/S | 3.56x | KR#2,023/2,419 Sec#125/231 |
| EV/EBITDA | 26.27x | KR#1,129/2,419 Sec#68/231 |
| FCF Yield | 6.18% | KR#773/2,419 Sec#37/231 |
| Profitability | ||
| ROE | 7.72% | KR#816/2,419 Sec#55/231 |
| ROA | 6.34% | KR#593/2,419 Sec#48/231 |
| Op. Margin | 12.11% | KR#413/2,419 Sec#35/231 |
| Revenue Growth | 12.12% | KR#798/2,419 Sec#78/231 |
| Financial Health | ||
| Debt Ratio | 21.81% | KR#411/2,419 Sec#50/231 |
| Total Debt | 76.33B KRW | KR#829/2,419 Sec#53/231 |
| FCF | 111.98B KRW | KR#182/2,419 Sec#9/231 |
| Cash | 266.52B KRW | KR#218/2,419 Sec#6/231 |
| Current Ratio | 4.62x | KR#314/2,419 Sec#53/231 |
| Net Debt/EBITDA | -3.08x | KR#158/2,419 Sec#5/231 |
| Dividend | ||
| Div. Yield | 2.57% | KR#722/2,419 Sec#36/231 |
| Div. Growth | 25.00% | KR#391/2,419 Sec#20/231 |
| Performance | ||
| 1Y Return | 53.77% | KR#260/2,419 Sec#10/231 |
| 1M Return | 23.41% | KR#243/2,419 Sec#18/231 |
| From 52W High | -4.20% | KR#27/2,419 Sec#2/231 |
| 1Y MDD | -23.60% | KR#116/2,419 Sec#9/231 |
| Trading | ||
| Volume | 893,722 shares | KR#126/2,419 Sec#21/231 |
| Trading Value | 35.26B KRW | KR#113/2,419 Sec#8/231 |
| Foreign Own. | 18.72% | KR#247/2,419 Sec#13/231 |
| Per Share | ||
| EPS | 1,718 KRW | KR#496/2,419 Sec#32/231 |
| BPS | 22,241 KRW | KR#497/2,419 Sec#35/231 |
Company Info
Seegene, established in 2000 and headquartered in Songpa-gu, Seoul, focuses on developing gene analysis technology and reagents. The company engages in the development, manufacturing, and sales of molecular diagnostic reagents that identify disease causes through gene analysis, possessing high-multiplex syndromic quantitative PCR technology. With agencies in over 100 countries including Italy, UAE, USA, and Canada, Seegene is actively expanding its global sales network and acquired 100% of Dandi Meka's shares in 2025.